Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06144242 · ClinicalTrials.gov registry record · NA
Improving Antibiotic Use for ARIs in Urgent Care Clinics
A NA study of Anti-bacterial Agents and Ambulatory Care, sponsored by Daniel Livorsi.
- Active
- Registry status
- NA
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT06144242: Active NA study of Anti-bacterial Agents and Ambulatory Care, sponsored by Daniel Livorsi.
NCT06144242 is a NA study of Anti-bacterial Agents and Ambulatory Care that is active but no longer recruiting, run by Daniel Livorsi. The registered enrollment target is 90 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06144242, a NA study of Anti-bacterial Agents and Ambulatory Care, is active but no longer recruiting, sponsored by Daniel Livorsi.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
Many clinicians prescribe antibiotics for patients with acute respiratory infections even when antibiotics will not benefit the patient because the infection is due to a virus. To discourage this type of unnecessary antibiotic use, the investigators will assess whether it is helpful to give clinicians feedback on how often they prescribe antibiotics for respiratory infections in comparison to their peers. The investigators will perform this study across Urgent Care and QuickCare clinics within a single healthcare system.
Primary Outcome
Percentage of all qualifying respiratory tract diagnosis (RTD) visits prescribed an antibiotic
Conditions Studied
Interventions
- BEHAVIORAL Feedback on RTD metric
Study Locations (1)
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2024-01-01 |
| Est. Completion | 2026-05-31 |
| Phase | NA |
What the registry record for NCT06144242 still lists
NCT06144242 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with Anti-bacterial Agents appearing as the primary indexed condition, and to 1 intervention - of which Feedback on RTD metric is the first listed.
NCT06144242 reports a single indexed study location in Iowa.
Frequently Asked Questions
What is clinical trial NCT06144242 about?
NCT06144242 is a clinical study titled "Improving Antibiotic Use for ARIs in Urgent Care Clinics". Many clinicians prescribe antibiotics for patients with acute respiratory infections even when antibiotics will not benefit the patient because the infection is due to a virus. To discourage this type of unnecessary antibiotic use, the investigators will assess whether it is helpful to give clinicia...
What is the current status of trial NCT06144242?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 90 participants. The study started on 2024-01-01. Estimated completion is 2026-05-31.
What conditions does trial NCT06144242 study?
This clinical trial studies the following conditions: Anti-bacterial Agents, Ambulatory Care.
What interventions are being tested in trial NCT06144242?
The interventions under investigation include: Feedback on RTD metric (BEHAVIORAL).
Who is sponsoring clinical trial NCT06144242?
This trial is sponsored by Daniel Livorsi, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06144242 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anti-bacterial Agents
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06144242's enrollment target sits among peer trials
90 941st of 2000 higher than 1,029 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI